The family Bunyaviridae is divided into five genera, of which four (Orthobunyavirus, Nairovirus, Phlebovirus, and Hantavirus) include numerous virus species capable of causing severe disease in both animals and humans. Well-known examples are hantavirus (HTNV; genus Hantavirus), Crimean-Congo hemorrhagic fever virus (CCHFV; genus Nairovirus), and Rift Valley fever virus (RVFV; genus Phlebovirus). Although RVFV, HTNV, and CCHFV cause severe disease with high fatality rates, no vaccines are available for the prevention of these diseases in humans, and no antiviral agents are registered for postexposure treatment. The development of such control tools is complicated by the fact that these viruses must be handled under high-level biosafety containment conditions.
In the veterinary field, RVFV is the most feared bunyavirus. The mortality rate in adult ruminants can be up to 20%, whereas fatality rates in unborn and young animals can be even more dramatic, approaching 100% (16, 17) . The human fatality rate is historically estimated to be below 1%, although considerably higher mortality rates have been reported (1, 2, 19) . RVFV is currently largely confined to the African continent and the Arabian Peninsula, but mosquitoes capable of transmitting RVFV are not restricted to these areas (33, 43, 44) . This explains the growing concern for RVFV incursions into previously unaffected areas, including Europe, Australasia, and the Americas (9, 10, 12, 22, 37) .
Like other bunyavirus family members, RVFV contains a three-segmented RNA genome, comprising a large (L), medium (M), and small (S) segment (21) . The L segment encodes the viral RNA polymerase. The M segment contains five in-frame start codons which give rise to the structural glycoproteins Gn and Gc and two major nonstructural proteins, referred to as NSm1 and NSm2 (Fig. 1) . The S segment encodes the nonstructural NSs protein and the nucleocapsid (N) protein. The NSs protein suppresses host innate immune responses and was shown to be the primary virulence factor of the virus (5, 13, 25, 34) .
The recent establishment of a reverse-genetics system for RVFV has provided important new insights into its biology (7, 12, 23, 26) . A few years after the first successful rescue of RVFV from cloned cDNA, the packaging of a reporter minigenome into virus-like particles (VLPs) was reported (24) . The VLPs were produced by transient expression of the NSm, Gn, Gc, N, and L proteins in the presence of the reporter minigenome. In this system, the N and L proteins produced from protein expression plasmids facilitate replication of the minigenome. The minigenome is subsequently packaged by the structural glycoproteins into so-called infectious VLPs (iVLPs), which are able to transport the RNA to receiving cells. Whereas primary transcription occurs in these cells, replication of the minigenome and high-level reporter gene expression depend on de novo production of N and L proteins from transfected plasmids (24) .
A recent study reported the copackaging of the M and S genome segments into VLPs (42) . Packaging of the L genome segment into VLPs was not accomplished in these studies, and it was proposed that the M genome segment, either alone or in a coordinated action with the S segment, is essential for packaging of the L segment. Here, we describe efficient methods for producing large amounts of virus particles that contain both S and L genome segments and thereby demonstrate that the M segment is not essential for this process. By virtue of the L and S genome segments, the particles are capable of autonomous genome replication and high-level gene expression. However, since the M genome segment is absent, the particles are incapable of autonomous spread. The so-called RVFV replicon particles (RRPs) were produced to titers exceeding 10 7 infectious particles/ml.
We propose that RVFV RRPs optimally combine the efficacy of live vaccines with the safety of inactivated vaccines and support this notion by demonstrating that a single intramuscular vaccination with 10 6 RRPs completely protects mice from a lethal dose of RVFV. We also show that RRPs can be used for rapid virus neutralization tests that do not require biosafety containment facilities.
The methods described here will greatly facilitate both fundamental and applied research on RVFV and can potentially be established for other members of the bunyavirus family as well.
MATERIALS AND METHODS
Cells and growth conditions. BSR-T7/5 cells were kindly provided by K. Conzelmann (Max von Pettenkofer-Institut, Munich, Germany). BSR-T7/5 cells, BHK cells, and derivatives were grown in Glasgow minimum essential medium (GMEM; Invitrogen, Carlsbad, CA) supplemented with 4% tryptose phosphate broth (Invitrogen), 1% minimum essential medium nonessential amino acids (MEM NEAA, Invitrogen), and 5 to 10% fetal bovine serum (FBS; Bodinco, Alkmaar, The Netherlands). For maintenance of stable cell lines, Geneticin (G-418; Promega, Madison, WI) was used at a concentration of 1 mg/ml. For the production of RRPs for the vaccination-challenge trial, cells were grown in Optimem (Invitrogen) supplemented with 2% FBS. Cells were grown at 37°C and 5% CO 2 . Drosophila (S2) cells were grown in Schneider's medium (Invitrogen) at 28°C. Aedes albopictus C6/36 cells were grown in Dulbecco's modified Eagle medium (Invitrogen) supplemented with 10% FBS at 28°C and 5% CO 2 .
Plasmids and viruses. Plasmid pCIneo-GnGc contains the open reading frame of the M segment of RVFV strain 35/74, starting at the fourth methionine codon. The Gn/Gc-coding sequence was codon optimized for optimal expression in mammalian cells and synthesized by the GenScript Corporation (Piscataway, NJ). Plasmids pCIneo-M and pCAGGS-M contain cDNA of the authentic RNA sequence of the M segment starting at the first methionine codon. Expression of genes from pCIneo is controlled by a cytomegalovirus (CMV) immediate-early enhancer/promoter, whereas the expression of genes from the pCAGGS plasmid is controlled by a CMV immediate enhancer/ß-actin (CAG) promoter (36) .
RVFV strain 35/74 was isolated from a liver of a sheep that died during an RVFV outbreak in the Free State province of South Africa in 1974 (3). The virus was passaged four times in mouse brain and three times in BHK cells. Amplification of the genome was performed by a one-step RT-PCR using primers previously described by Bird et al. (8) . PCR products were purified from agarose gels and used for GS FLX sequencing at Inqaba Biotec (Pretoria, South Africa) essentially as described previously (40) . The consensus sequences corresponding to each genome segment were synthesized and cloned in pUC57, a standard cloning vector of the GenScript Corporation (Piscataway, NJ). pUC57-L, pUC57-M, and pUC57-S encode the RVFV L, M, and S genome segments, respectively, in antigenomic orientation. The complete sequence of the L, M, and S genome sequences can be found in GenBank under the accession numbers JF784386, JF784387, and JF784388, respectively. Of note, the cDNA of the M segment present in plasmid pUC57-M contains a silent A-to-G mutation at position 182. The transcription plasmids each contain a complete copy of the viral RNA segments and are flanked by a minimal T7 promoter and a hepatitis delta virus ribozyme sequence. In pUC57-S-eGFP, the NSs gene is replaced by the gene encoding enhanced green fluorescent protein (eGFP) (Fig. 1, inset) .
Rescue of recombinant RVFV strain 35/74. BSR-T7/5 cells were seeded in six-well plates and were cotransfected with 1 g of plasmids pUC57-L, pUC57-M, and pUC57-S using jetPEI transfection reagent according to the instructions of the manufacturer (Polyplus-transfection SA, Illkirch, France). After 6 days of incubation, the medium was collected and used for virus titration on BHK cells.
Alternatively, BHK cells were infected with a recombinant fowlpox virus (FPV) that produces T7 polymerase (15, 18) . This virus, named fpEFLT7pol (referred to here as FP-T7), was previously kindly provided by the Institute for Animal Health (IAH, Compton, United Kingdom). After incubation with FP-T7 for 1 h and recovery for another hour, the cells were treated as described for BSR-T7/5 cells. Virus titers were determined as 50% tissue culture infective doses (TCID 50 ) using BHK cells and were calculated using the Spearman-Kärber method (27, 41) .
Production of RRPs. For the production of RRPs using the three-plasmid system, BHK or BHK-GnGc cells were seeded in six-well plates and incubated with FP-T7 for 1.5 to 2 h at 37°C. Medium was refreshed, and cells were allowed to recover for 1 h. Cells were subsequently transfected with 600 ng each of pUC57-L, pUC57-S-eGFP, and pCAGGS-M. The medium was refreshed the next day. Supernatants were harvested after 72 h, precleared by low-speed centrifugation at room temperature, and stored at 4°C until further use.
For the production of RRPs using the one-plasmid system, HEK293T cells were seeded in six-well plates and infected with RRPs at a multiplicity of infection (MOI) of 3. Three days later, the cells were passaged in the wells of a 6-well plate and transfected with 1 g of pCAGGS-M. RRPs were collected from the culture medium at 72 h posttransfection. Alternatively, BHK-Rep cells were transfected with pCAGGS-M, and RRPs were collected at different time points.
The titers of RRPs were determined by TCID 50 assays using BHK cells and were calculated using the Spearman-Kärber method (27, 41) . Infectivity was detected by monitoring eGFP expression using a Zeiss fluorescence microscope.
For the production of RRPs for vaccination of mice, BHK-Rep cells were grown in Optimem supplemented with 2% FBS. The cells were transfected with pCAGGS-M, and after 24 h the medium was collected. The RRPs in the collected medium were concentrated using Amicon filters (Millipore, Billerica, MA) and subsequently diluted in PBS to a titer of 10 7.3 TCID 50 /ml. Northern blotting. RNA probes were prepared by T7-based in vitro transcription in the presence of digoxigenin-11-UTP according to the instructions provided with the DIG Northern starter kit (Roche, Woerden, The Netherlands). Templates for in vitro transcription were produced by PCR using cDNA of the S, M, and L segments as the template and dedicated primers containing the T7 promoter sequence. The S probe comprised nucleotides 1 to 378 of the S Viral RNA of recombinant RVFV strain 35/74 (r35/74) was extracted with a High Pure viral RNA kit (Roche) according to the instructions of the manufacturer. RVFV RNA from the BHK-Rep and BHK-Rep2 cells was extracted using the RNeasy kit according to the instructions of the manufacturer (Qiagen, Hilden, Germany). RNA was separated by electrophoresis using the glyoxaldimethyl sulfoxide system provided with the Northern-Max-Gly kit (Ambion, Austin, TX). Size-fractionated RNA was transferred by blotting onto positively charged nylon membranes (Roche) using the transfer buffer of the NorthernMax-Gly kit. RNA was fixed on the membrane by baking at 80°C for 30 min. Hybridization of digoxigenin (DIG)-labeled RNA probes was performed using UltraHyb hybridization buffer and wash solutions according to the recommendations of the manufacturer (Ambion).
Detection of hybridized probes was performed using the DIG Northern starter kit (Roche) according to the manufacturer's protocol. Briefly, blots were incubated in blocking solution for 30 min and subsequently incubated with alkaline phosphatase-conjugated anti-DIG antibody for 30 min, followed by washing twice in washing buffer. After equilibration in detection buffer, blots were incubated with the chemiluminescent substrate supplied by the DIG kit (CDP-Star) and exposed to X-ray films (Amersham Hyperfilm).
Polyacrylamide gel electrophoresis (PAGE) and Western blotting. Proteins were separated in bis-Tris gradient gels (Invitrogen) and analyzed by Western blotting as described previously (28) . For Western blot analysis of Gn and Gc, rabbit peptide antisera were used (20) . Monoclonal antibody (MAb) F1D11 (kindly provided by Alejandro Brun, CISA-INIA, Madrid, Spain) was used for the detection of the N protein.
IPMAs. Immunoperoxidase monolayer assays (IPMAs) were performed as described previously (20) . For the detection of the Gn and Gc proteins, a polyclonal sheep antiserum was used (28) .
Flow cytometry. Flow cytometry was performed using a CyAn ADP flow cytometer (Beckman Coulter) equipped with a 488 nm laser. For the analysis of the data, Summit v4.3 software was used.
Transmission electron microscopy (TEM). RRPs were applied to carboncoated copper Formvar grids (Stork Veco BV, Eerbeek, The Netherlands). The grids were stained with 1% phosphotungstate (PTA) at pH 7 (Merck, Darmstadt, Germany). Images were recorded at a calibrated magnification of ϫ60,000 using a FEI Tecnai 12 electron microscope.
VNTs using RRPs. Classical and RRP virus neutralization tests (VNTs) were performed with sera from lambs that had previously been experimentally infected with the 35/74 virus. To confirm the presence of RVFV-specific antibodies, the sera were analyzed with a recombinant N (recN) RVFV enzyme-linked immunosorbent assay (ELISA) (BDSL, Irvine, Ayrshire, Scotland, United Kingdom) prior to analysis by VNT. The classical VNT was performed as described previously (20) . For the RRP VNT, serum dilutions were prepared in 96-well plates in 50 l GMEM supplemented with 5% FBS, 4% tryptose phosphate broth (TPB), 1% MEM NEAA, and 1% penicillin-streptomycin. Culture medium containing ϳ200 RRPs in a 50-l volume was added to the serum dilutions and incubated for 1.5 h at room temperature. Next, 50 l of growth medium containing 40 000 BHK cells was added to each well. Plates were incubated at 37°C and 5% CO 2 . After 36 to 48 h, the neutralization titer was calculated by the Spearman-Kärber method (27, 41) .
Vaccination and challenge of mice. Female BALB/c mice (Charles River Laboratories, Maastricht, The Netherlands) were housed in groups of five animals and kept under biosafety level 3 containment. Groups of 10 mice were vaccinated via the intramuscular or subcutaneous route either once, on day 21, or twice, on days 0 and 21, with 10 6 TCID 50 of RRPs in 50 l PBS. One group of nine mice was left untreated. The body weights of the mice were monitored weekly. On day 42, all mice were challenged via the intraperitoneal route with 10 2.7 TCID 50 of RVFV strain 35/74 in 0.5 ml culture medium. Challenged mice were monitored daily for visual signs of illness and mortality.
This experiment was approved by the Ethics Committee for Animal Experiments of the Central Veterinary Institute of Wageningen University and Research Centre.
RESULTS
Establishment of a three-plasmid system for the production of RRPs. RVFV strain 35/74 was readily rescued from cDNA by transfection of BSR-T7/5 cells with plasmids pUC57-S, pUC57-M, and pUC57-L encoding the viral RNA segments in antigenomic orientation. Our next aim was to produce only the L and S genome segments and to package these segments into RRPs by providing the structural glycoproteins Gn and Gc in trans from a protein expression plasmid. To facilitate monitoring of genome replication, a reporter minigenome was produced in which the nonessential NSs gene of the S genome segment is replaced by the enhanced green fluorescent protein (eGFP) gene (Fig. 1, inset) . The resulting plasmid was named pUC57-S-eGFP. Cotransfection of pUC57-L and pUC57-SeGFP into BSR-T7/5 cells resulted in only very few eGFPpositive cells, and cotransfection with a plasmid providing the NSm, Gn, and Gc proteins (i.e., pCAGGS-M) did not result in the production of RRPs.
To improve the system, we evaluated the use of a recombinant fowlpox virus as a source of T7 polymerase (15, 18) . The pUC57-S plasmid was transfected on its own into BSR-T7/5 cells and into BHK cells that had been infected with FP-T7 prior to transfection. Whereas the N protein was not detected in BSR-T7/5 cells transfected with pUC57-S, FP-T7-infected BHK cells that were transfected with this plasmid stained intensely with a monoclonal antibody (MAb) specific for the N protein (Fig. 2) .
BHK cells were infected with the fowlpox virus (FP-T7) and subsequently transfected with pUC57-S-eGFP only, cotransfected with pUC57-S-eGFP and pUC57-L, or cotransfected with pUC57-S-eGFP, pUC57-L, and pCAGGS-M. Transfection with only pUC57-S-eGFP did not result in eGFP expression (Fig. 3A) . After 72 h, eGFP expression was observed in a small percentage (0.33%) of cells that were cotransfected with pUC57-S-eGFP and pUC57-L. However, when pCAGGS-M was added to the transfection mixture, about one quarter of the cells expressed eGFP (Fig. 3A) . This finding suggested that infectious particles were formed upon introduction of the pCAGGS-M plasmid, resulting in an increase in the number of eGFP-expressing cells. Collected supernatant was added to BHK cell monolayers, and after 36 h, infection was monitored by fluorescence microscopy. Only cells incubated with the supernatant obtained from cells transfected with all three plasmids exhibited eGFP expression. This confirmed that we were successful in producing RVFV replicon particles (RRPs). Three independently performed experiments yielded an average RRP titer of 10 4.8 TCID 50 /ml. The three-plasmid sys- tem for the production of RRPs is schematically depicted in Fig. 3B .
Establishment of a one-plasmid system for the production of RRPs. The RRP titers obtained with the three-plasmid system never exceeded 10 5 TCID 50 /ml. To develop a system for the continuous production of high-titer RRPs, we created stable BHK cell lines that constitutively produce the Gn and Gc proteins. BHK cells were transfected with pCIneo-GnGc, and clones with integrated plasmids were grown in the presence of G-418. Whereas an anti-Gn/Gc serum revealed clear glycoprotein expression 1 to 2 days after transfection, after cloning of the cells, only very few selected clones revealed Gn/Gc expression by IPMA, and in all cases, expression seemed very low. One clone that revealed the most intense staining in IPMAs (Fig. 4) was selected and named BHK-GnGc.
It was previously demonstrated that expression of the Gn and Gc proteins in both mammalian (31) and insect cells (20) results in the production of VLPs. To determine if VLPs were produced by BHK-GnGc cells, supernatants were ultracentrifuged (100,000 ϫ g, 2 h), and the proteins in the collected pellets were analyzed by Western blotting. Neither the Gn nor the Gc protein was detected in the pellet fractions (data not shown), suggesting either that no VLPs were produced or, more likely, that glycoprotein production was too low to allow detection.
Although the BHK-GnGc cells apparently produced only very limited amounts of Gn and Gc, we hypothesized that these cells might tolerate Gn/Gc expression from plasmids to a greater extent than normal BHK cells and therefore be more suitable for RRP production. To substantiate this hypothesis, BHK-GnGc cells were infected with FP-T7 and subsequently cotransfected with the three plasmids. In an attempt to increase the number of eGFP-expressing cells, the cells were next transfected with pCAGGS-M only. This whole procedure was then repeated, followed by two cell passages and introduction of the pCAGGS-M plasmid (Fig. 5A) . At this point, flow cytometry demonstrated that Ͼ90% of the BHK-GnGc cells were positive for eGFP expression. The resulting cell line, which maintains the L genome segment and the S-eGFP minigenome, was designated BHK-Rep. Transfection of BHK-Rep cells with pCAGGS-M after cell passages 83, 103, and 105 yielded an average RRP titer of 10 6.7 TCID 50 /ml. It is important to note that we also used a similar protocol starting with wild-type BHK cells instead of BHK-GnGc cells. In these experiments, reporter gene expression did not continue to increase, and we were therefore unable to produce a cell line with Ͼ90% reporter gene expression using this procedure.
The NSm protein was previously reported to suppress virusinduced apoptosis (45), so we reasoned that a cell line constitutively expressing not only Gn and Gc but also the NSm proteins could be more efficient in the constitutive production of RRPs by suppressing apoptosis. To this end, we aimed to produce a BHK-Rep cell line with a stably integrated plasmid encoding the NSm, Gn, and Gc proteins (i.e., pCIneo-M). For convenience, the L and S-eGFP genome segments were introduced into BHK cells not by transfection of plasmids but instead by infection of the cells with RRPs combined with transfection with pCAGGS-M. Cells were passaged and subsequently transfected with pCIneo-M and grown in the presence of G-418. In this way, BHK-Rep cells were produced without introducing FP-T7 and the transcription plasmids. The cells were used for cloning by endpoint dilution, and a selected clone was named BHK-Rep2. The steps followed to produce the BHK-Rep2 cell line are depicted in Fig. 5B . Although this cell line also did not constitutively produce RRPs, transfection of this cell line with the pCAGGS-M plasmid yielded an average RRP titer of 10 7.2 TCID 50 /ml (n ϭ 6). To determine if other mammalian and insect cells can be infected with RRPs, human embryonic kidney 293 cells (HEK293T), Drosophila S2 cells, and Aedes albopictus C6/36 cells were infected with RRPs at an MOI of 1 (calculated using the titer determined on BHK cells). This experiment demonstrated that both mammalian and insect cells can be readily infected with RRPs (Fig. 6) . Expression of eGFP in mammalian cells and insect cells was optimal at 42 and 72 h postinfection, respectively.
It is important to note that the one-plasmid system is not restricted to BHK-Rep cells. Transfection of RRP-infected HEK293T cells with the pCAGGS-M plasmid yielded an RRP titer of 10 6.5 TCID 50 /ml. This demonstrates that alternative cell types can be used for the production of RRPs by combining an RRP infection with a transfection of the pCAGGS-M plasmid (Fig. 7) .
Characterization of BHK-Rep cells. Persistence of RVFV RNA in cells was previously reported by Billecocq et al. (6).
Those authors detected defective interfering (DI) RNAs with large internal deletions and suggested that these DI RNAs could be responsible for the persistent infection. Considering this, we determined whether abnormal viral RNA segments were present in the BHK-Rep and BHK-Rep2 cells. Northern blotting was performed with total RNA extracted from BHKRep and BHK-Rep2 cells at cell passage 13 and 45, respectively. S-, M-, and L-specific probes revealed only the S and L segments, confirming that no M segment is present in the BHK-Rep cells (Fig. 8) . The S-eGFP and L segments were detected at the same positions as the S and L segments of the recombinant virus, suggesting that no significant levels of DI RNAs were present.
To determine if mutations were introduced upon replication of the L and S-eGFP genome segments in BHK-Rep cells, cDNA was produced and sequenced, with the exception of the primer binding regions on the extreme 3Ј and 5Ј ends, using standard techniques. Only a single mutation (G11813A) was detected in the L genome segment present in the BHK-Rep cells, resulting in an amino acid change from glycine to glutamic acid at position 388 of the L protein. This mutation was also detected in the BHK-Rep2 cells, together with a silent mutation in the L gene (A16023C) and two mutations in the 5Ј untranslated region (T63253C and T63673C). In the SeGFP segments, only a single silent mutation was detected in the BHK-Rep2 cells (C653T). The number of the mutations corresponds to their position in the antigenomic-sense RNA. We did not study the effect of these mutations further.
The viral RNA segments were introduced in BHK-Rep cells by plasmids that were transcribed by the FP-T7 virus. Although it is well established that FPV does not replicate in mammalian cells (15) , the BHK-Rep and BHK-Rep2 cells were tested for the presence of FP-T7 by PCR. No FPV DNA was detected in these assays (data not shown).
Characterization of RRPs. To establish the kinetics of RRP production, BHK-rep cells were transfected with pCAGGS-M, and the culture medium was collected at different time points posttransfection. This experiment demonstrated that the titer was already close to 10 6 TCID 50 /ml after 22 h (Fig. 9A) . To demonstrate that RRPs are incapable of autonomous spread, BHK cells were infected with RRPs at an MOI of 1. After 2 days, eGFP expression was observed by fluorescence microscopy (Fig. 9B, left) . BHK cells were incubated with the collected precleared supernatant, and after 3 days, cells were monitored for eGFP expression. No eGFP expression was observed, demonstrating that no progeny infectious particles were produced by the RRP-infected BHK cells (Fig. 9B, right) .
To visualize RRPs by transmission electron microscopy (TEM), BHK-Rep2 cells were transfected with pCAGGS-M. After 30 h, the RRPs present in precleared culture supernatant were concentrated using Amicon filters and subsequently used to coat carbon-coated Formvar grids. Grids were stained with To visualize RRP proteins, RRPs were pelleted by ultracentrifugation. The proteins were separated in polyacrylamide gels, transferred to nitrocellulose membranes, and detected using peptide antisera specific for the Gn and Gc proteins or a MAb specific for the N protein. Analysis of the supernatant obtained from nontransfected BHK-Rep cells revealed only the N protein (Fig. 9D) . This result suggests that the RVFV N protein is released from cells, resembling results previously obtained in studies on CCHFV (4). Analysis of supernatant from BHK-Rep cells transfected with pCAGGS-M revealed the NSm1 protein, the Gn and Gc proteins, and the N protein (Fig. 9D) .
Establishment of a novel VNT. To determine if RRPs can be used in VNTs, sera obtained from experimentally infected lambs were used in the classical VNT as described previously (20) and used in a novel VNT that uses RRPs instead of live virus. The sera were also tested by ELISA. As is done with the complete virus in the classical VNT, serum dilutions were preincubated with RRPs, and the mixtures were subsequently incubated with BHK cells. Whereas in the classical VNT, the lack of neutralization is detected by cytopathic effect, in the RRP VNT, eGFP expression demonstrates lack of neutralization. Titers are determined in both assays using the SpearmanKärber method (27, 41) .
The experiment revealed that the so-called RRP VNT has an optimal readout between 36 and 48 h and has a sensitivity equal to, if not higher than, that of the classical VNT (Table 1) .
Vaccination and challenge of mice. To study the vaccine efficacy of RRPs, groups of 10 mice were immunized with 50 l of an inoculum containing 10 6 TCID 50 of RRPs, via either the subcutaneous or intramuscular route, either once or twice with a 3-week interval. One group of 9 nonvaccinated mice was added as a control group. The mice were challenged on day 42 with a known lethal dose of RVFV strain 35/74. All nonvaccinated mice displayed overt clinical signs and weight loss, and eight of a total of nine nonvaccinated mice succumbed to the infection within 4 days after challenge. One mouse survived for 12 days but eventually died. The survival rate in the groups of mice vaccinated either once or twice via the subcutaneous route was 60%. In contrast, 100% of the mice vaccinated via the intramuscular route, either once or twice, survived the challenge (Fig. 10) . These mice did not show any clinical signs or weight loss throughout the experiment. This demonstrates that a single intramuscular vaccination with 10 6 RRPs can protect mice from a lethal dose of RVFV.
DISCUSSION
Here, we report the creation of a nonspreading bunyavirus. Critical to the production of the RVFV replicon particles (RRPs) was the use of FPV as a source of T7 polymerase. Despite much effort, production of RRPs using BSR-T7/5 cells, which are routinely used for bunyavirus reverse genetics, never succeeded.
Rescue of a bunyavirus requires only three T7 transcripts representing the viral RNA molecules in antigenomic-sense orientation. This suggests that the antigenomes act not only as replication intermediates but also as mRNAs (30) . Although in our experiments, expression of the N protein from antigenomic-sense S RNA was not detectable in BSR-T7/5 cells, expression was readily detected in FP-T7-infected cells. T7-based transcription in BSR-T7/5 cells results in uncapped RNAs, whereas the FP-T7 virus provides its own capping enzyme (15) . We propose that this explains the improved gene expression from antigenomic viral RNAs and thereby the superiority of FP-T7-infected cells over BSR-T7/5 cells to drive minigenome expression.
It is interesting that the first rescue of a bunyavirus (i.e., Bunyamwera virus [BUNV]) from cDNA was performed using another poxvirus, namely, vaccinia virus (VV), as a source of T7 polymerase (i.e., vTF7-3) (14) . The protocol for BUNV rescue was later adapted to use BSR-T7/5 cells, which circumvented the need to remove the VV from the culture medium after bunyavirus rescue (30) . In our studies, we preferred FPV over VV for providing T7 polymerase, since the former not only is much less cytopathic but also does not replicate in mammalian cells (15) . There is thus no FPV to be removed from the culture medium after rescue of a bunyavirus.
Although production of RRPs using the initially established three-plasmid system is highly reproducible, yields of RRPs using this system never exceeded 10 5 TCID 50 /ml. We therefore By establishing the BHK-Rep cells, a one-plasmid system for the production of RRPs was provided that can reproducibly yield titers of up to 10 7 TCID 50 /ml even after 100 cell passages. We also demonstrate that the one-plasmid system is not restricted to using BHK-Rep cells. When combining an infection with RRPs with a transfection of the plasmid encoding the structural glycoproteins, any mammalian or insect cell can potentially be used for the production of RRPs and the use of FP-T7 and the transcription plasmids is no longer required. To underscore this notion, we show that HEK293T cells can be used for the efficient production of RRPs.
The VNT is the gold-standard diagnostic assay for the serologic confirmation of RVFV infection and the prescribed test for animal trade (36a). The classical VNT requires handling of live RVFV and must therefore be performed in appropriate biosafety containment facilities. Another drawback of the classical VNT is that the assay requires 5 to 7 days for completion. We show that eGFP-expressing RRPs can be used for VNTs that do not require biocontainment facilities and that this socalled RRP-VNT requires only 24 to 48 h for completion. Apart from the RRPs developed in the current work, attenuated viruses containing the eGFP gene can potentially be similarly applied.
Finally, we demonstrate that RRPs can be used as a highly effective vaccine. We and others have previously reported efficient VLP production systems and VLPs comprising only the Gn and Gc proteins are highly effective vaccine candidates (20, 29, 31, 32, 35, 38) . Mandell et al. demonstrated that including the N protein in VLPs improves vaccine efficacy (31) , which could be due to stabilization of the particle and/or to partial protective efficacy mediated by the N protein alone (11) . It was subsequently reported that so-called infectious VLPs capable of primary transcription of the N gene are remarkably effective, providing complete protection in mice after a single vaccination (38) . The RRPs produced in the current work could be even more efficacious, since the particles are capable of autonomous genome replication and high-level gene expression. Replication of the RRP genome in vivo could induce interferon and other innate immune responses and in vivo production of the L and N proteins could also induce adaptive cellular immune responses. Although additional studies are required to characterize in detail the innate and adaptive immune responses elicited by RRPs, we already demonstrate here that a single intramuscular vaccination with RRPs protects mice against a lethal challenge dose. Experiments are planned to study the immune response elicited by RRP vaccination in detail and to study the vaccine efficacy of RRPs in sheep.
Apart from applied research, our methods will also facilitate studies on RVFV genome replication and packaging. In this respect, it is interesting that the current work already demonstrates that the M genome segment is not required for packaging of the L segment, contrasting a recent suggestion (42) . Our system is also particularly useful for functional studies on the structural glycoproteins Gn and Gc. Mutations can be easily introduced in the pCAGGS-M plasmid, and their effects on host cell attachment, entry, and fusion can be studied independently. Since the system does not depend on live virus, even the nature of lethal mutations can be studied. An alternative system that can be used for such studies is the previously described system for producing iVLPs (24, 38, 39) . Reporter gene expression in iVLP-infected cells, however, requires cotransfection with helper plasmids, which likely renders this system more prone to experimental variation than the oneplasmid system described here.
In summary, the methods reported here allow both fundamental and applied research on RVFV to be conducted outside biocontainment facilities and will therefore greatly facilitate the development of novel therapeutics and vaccines for the control of RVFV. A newly identified member of the phlebovirus genus causing severe fever with thrombocytopenia syndrome (SFTS) in humans recently emerged in China (46) , and members of other genera of the bunyavirus family, such as CCHFV and HTNV, also continue to be of serious public health concern. The methods described here could facilitate the future control of these highly pathogenic bunyaviruses as well.
